2186 — Luye Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapValue Trap

Annual income statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,540	5,200	5,982	6,143	6,061
Cost of Revenue
Gross Profit	3,991	3,397	4,141	4,204	4,044
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,175	4,876	4,841	4,768	4,660
Operating Profit	1,364	324	1,141	1,375	1,402
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	942	-74.6	670	700	839
Provision for Income Taxes
Net Income After Taxes	703	-145	583	539	645
Minority Interest
Net Income Before Extraordinary Items
Net Income	707	-134	605	533	472
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	707	-134	605	533	472
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.221	0.01	0.191	0.144	0.128
Dividends per Share